Endothelial-Derived Hyperpolarizing Factor (EDHF): Is there more than one?

Christopher Triggle, H. D. Dong, Hong Ding, G. J. Waldron, W. C. Cole

Research output: Contribution to journalArticle


It is now well established that the pharmacological properties of EDRF reflect those of nitric oxide (NO). Furthermore, in some blood vessels, prostacyclin (PGI2) also contributes to endothelium-dependent vasorelaxation. However, there is now increasing evidence, particularly from resistance vessels, that a factor(s), other than NO or PGI2, may play an important role in mediating endothelium-dependent hyperpolarization of vascular smooth muscle (Mombouli & Vanhoutte, 1997; Waldron et al. 1996). Recent studies from our laboratory indicate that in a large conduit vessel, the rabbit carotid artery, EDHF possesses the properties of a cytochrome P450 arachidonic acid product (Dong et al. 1997), whereas in mesenteric vessels from both the guinea pig and the rat, cytochrome P450 inhibitors have minimal effects on non-NO/PGI2 endothelium-dependent vasorelaxation. These data strongly suggest that EDHF is not a single entity and that tissue and species differences may exist.

Original languageEnglish
Pages (from-to)286-287
Number of pages2
JournalProceedings of the Western Pharmacology Society
Publication statusPublished - 1998
Externally publishedYes


ASJC Scopus subject areas

  • Pharmacology

Cite this